Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

(2022) Sabrina H. Tsang et al.   npj Vaccines

Real-world Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer

(2021) Susanne K Kjaer et al.   JNCI-Journal of the National Cancer Institute

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study

(2021) Milena Falcaro et al.   LANCET

Human Papillomavirus Genotype Replacement: Still Too Early to Tell?

(2020) Irene Man et al.   JOURNAL OF INFECTIOUS DISEASES

Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: the CVT Trial

(2020) Sabrina H Tsang et al.   JNCI-Journal of the National Cancer Institute

Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial

(2020) Aimée R Kreimer et al.   JNCI-Journal of the National Cancer Institute

HPV Vaccination and the Risk of Invasive Cervical Cancer

(2020) Jiayao Lei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

(2020) Carolina Porras et al.   LANCET ONCOLOGY

HPV-testing versus HPV-cytology co-testing to predict the outcome after conization

(2018) Laerke Valsøe Bruhn et al.   ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

(2017) Joseph E. Tota et al.   JNCI-Journal of the National Cancer Institute

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

(2017) Joseph E. Tota et al.   JNCI-Journal of the National Cancer Institute

Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica

(2015) Paula Gonzalez et al.   VACCINE

Are 20 human papillomavirus types causing cervical cancer?

(2014) Marc Arbyn et al.   JOURNAL OF PATHOLOGY

Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination

(2013) J. E. Tota et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types

(2013) Davit Bzhalava et al.   VIROLOGY

Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: Quantification using a multi-type mathematical model

(2012) Yoon Hong Choi et al.   VACCINE

Serotype replacement in disease after pneumococcal vaccination

(2011) Daniel M Weinberger et al.   LANCET

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study

(2010) Koji Matsumoto et al.   INTERNATIONAL JOURNAL OF CANCER

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

(2008) Rolando Herrero et al.   VACCINE